Results 41 to 50 of about 584 (117)
Immunology &Cell Biology, Volume 94, Issue 2, Page 185-195, February 2016., 2016 Chlamydia is the most widespread sexually transmitted bacterial disease and a prophylactic vaccine is highly needed. Ideally, this vaccine is required to induce a combined response of Th1 cell‐mediated immune (CMI) response in concert with neutralizing antibodies.
Sarah Bøje +6 more
wiley +1 more source
EBioMedicine, 2018 Despite inducing strong T cell responses, Mycobacterium tuberculosis (Mtb) infection fails to elicit protective immune memory. As such latently infected or successfully treated Tuberculosis (TB) patients are not protected against recurrent disease. Here,
Thomas Lindenstrøm +5 more
doaj +1 more source
Vaccine Adjuvants Differentially Affect Kinetics of Antibody and Germinal Center Responses
Frontiers in Immunology, 2020 Aluminum salts and squalene based oil-in-water emulsions (SE) are widely used adjuvants in licensed vaccines, yet their mechanisms are not fully known.
Gabriel Kristian Pedersen +4 more
doaj +1 more source
Mucosal Vaccine Development Based on Liposome Technology
Journal of Immunology Research, Volume 2016, Issue 1, 2016., 2016 Immune protection against infectious diseases is most effective if located at the portal of entry of the pathogen. Hence, there is an increasing demand for vaccine formulations that can induce strong protective immunity following oral, respiratory, or genital tract administration.
Valentina Bernasconi +5 more
wiley +1 more source
Scientific Reports, 2022 Liposomes are a strong supporting tool in vaccine technology, as they are a versatile system that not only act as antigen delivery systems but also adjuvants that can be highly effective at stimulating both innate and adaptive immune responses.
Laura A. J. Feather +5 more
doaj +1 more source
Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research
BioMed Research International, Volume 2013, Issue 1, 2013., 2013 There is no malaria vaccine currently available, and the most advanced candidate has recently reported a modest 30% efficacy against clinical malaria. Although many efforts have been dedicated to achieve this goal, the research was mainly directed to identify antigenic targets.
Elena Mata +5 more
wiley +1 more source
PLoS ONE, 2018 There is a need for the rational design of safe and effective vaccines to protect against chronic bacterial pathogens such as Mycobacterium tuberculosis and Mycobacterium avium subsp. paratuberculosis in a number of species.
Aneesh Thakur +6 more
doaj +1 more source
Tuberculosis Research and Treatment, Volume 2011, Issue 1, 2011., 2011 Mycobacterium bovis bacille Calmette‐Guérin (BCG) is the only available vaccine for tuberculosis (TB). Although this vaccine is effective in controlling infantile TB, BCG‐induced protective effects against pulmonary diseases in adults have not been clearly demonstrated.
Kazuhiro Matsuo +2 more
wiley +1 more source
Frontiers in Immunology, 2022 Successful subunit vaccination with recombinant proteins requires adjuvants. The glycolipid trehalose-dibehenate (TDB), a synthetic analog of the mycobacterial cord factor, potently induces Th1 and Th17 immune responses and is a candidate adjuvant for ...
Christiane Desel +9 more
doaj +1 more source
Frontiers in Immunology, 2018 Influenza epidemics occur annually, and estimated 5–10% of the adult population and 20–30% of children will become ill from influenza infection. Seasonal vaccines primarily work through the induction of neutralizing antibodies against the principal ...
Dennis Christensen +6 more
doaj +1 more source